In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:
- Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractory AML
- Phase I/II study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory FLT3-mutant AML
- A retrospective comparison of abbreviated course 7+7 vs standard HMA plus venetoclax doublet in older/unfit patients with newly diagnosed AML
- Multisite randomized trial of a collaborative palliative and oncology care model for patients with AML and myelodysplastic syndromes (MDS) receiving nonintensive therapy
- Final 5-year results from the phase II pivotal cohort of olutasidenib for IDH1-mutated AML
- Post hoc analyses of outcomes in patients with AML and MDS-related changes who received oral azacitidine maintenance therapy in the phase III QUAZAR AML-001 study
- First-in-human phase I/II of the menin-MLL inhibitor DSP-5336 in patients with R/R acute leukemia: updated results from the dose escalation phase
- A phase Ib study of the menin-KMT2A inhibitor bleximenib in combination with venetoclax and azacitidine in R/R AML with alterations in KMT2A or NPM1
Program faculty:
Eunice S. Wang, MD
Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Courtney DiNardo, MD, MSCE
Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas
Resources:
To download the slides associated with this podcast discussion, please visit the program page:
https://bit.ly/4bvJGij
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
